adg2 Antibody

What is ADG2 antibody and how does it differ from conventional SARS-CoV-2 monoclonal antibodies?

ADG2 antibody is an engineered monoclonal antibody developed for both treatment and prevention of COVID-19. Unlike most clinical-stage antibodies that trade breadth for potency, ADG2 demonstrates both high neutralization potency against SARS-CoV-2 (IC50 of ~1 ng/mL) and exceptional breadth against other sarbecoviruses, including SARS-CoV (IC50 of 4-8 ng/mL) .

The antibody's key distinguishing factor is its ability to target a highly conserved epitope that overlaps the receptor binding site, described as an "Achilles' heel" for clade 1 sarbecoviruses . While most anti-SARS-CoV-2 antibodies recognize epitopes that are highly variable among other sarbecoviruses (limiting their neutralization breadth and increasing susceptibility to escape mutations), ADG2 employs a distinct angle of approach to recognize this conserved epitope .

What is the relationship between ADG2 and ADG20?

ADG20 is a half-life extended version of ADG2 . The engineering of ADG20 from ADG2 was designed to potentially offer protection against COVID-19 for up to a year . This extended half-life makes ADG20 particularly suitable for prophylactic applications, where longer duration of protection is desirable.

The development pathway progressed from isolating antibodies from a SARS-CoV survivor, introducing diversity through yeast display libraries, screening for binding to SARS-CoV-2, and then engineering for extended half-life . ADG20 entered Phase 1 clinical studies in early 2021 .

How does ADG2 perform against SARS-CoV-2 variants of concern?

ADG2 maintains potent neutralization activity against all tested SARS-CoV-2 variants. Specifically:

• It displayed little to no reduction (<4-fold) in neutralizing activity across three variants of concern (P.1, B.1.351, B.1.1.7), with all reaching a plateau at 100% neutralization .

• ADG2 retained activity against the D614G variant, which emerged as the dominant pandemic strain .

• When tested against 36 naturally circulating SARS-CoV-2 variants (including those reported to be resistant to certain antibodies), ADG2 bound to all variants at levels ≥50% of those for wild-type SARS-CoV-2 .

This broad coverage against variants contrasts with other clinical antibodies like ADG-1, CB6/LY-CoV16, LY-CoV555, REGN10987, and REGN10933, which exhibited loss of binding (>75% reduction relative to wild-type) to one or more SARS-CoV-2 variants .

What evidence supports ADG2's cross-neutralization capabilities against other coronaviruses?

ADG2 demonstrates remarkable cross-neutralization capabilities against multiple coronaviruses:

• It shows high neutralization potency against authentic SARS-CoV and two bat SARS-related viruses, with IC50 values between 4 and 8 ng/ml .

• It bound with high affinity to receptor binding domains (RBDs) of 12 out of 13 clade 1 SARS-like coronaviruses, with KD(APP) of 0.24–1.12 nM .

• In animal models, ADG2 provided complete protection against both SARS-CoV-2 and SARS-CoV challenge .

This evidence suggests ADG2 has potential utility not only against current pandemic strains but also against future coronavirus threats that may emerge from bat reservoirs .

What epitope does ADG2 target, and how does this contribute to its broad neutralization capabilities?

ADG2 targets a highly conserved epitope that overlaps the receptor binding site on the spike protein of coronaviruses . This epitope is described as an "Achilles' heel" for clade 1 sarbecoviruses due to its conservation across multiple viruses in this group .

The conservation of this epitope explains two key advantages of ADG2:

• Neutralization breadth: By targeting a region that remains largely unchanged across different sarbecoviruses, ADG2 can effectively bind to and neutralize multiple viruses within this group.

• Resistance to escape mutations: The conserved nature of the epitope suggests evolutionary constraints that limit the virus's ability to mutate this region without compromising viral fitness. This explains why ADG2 retains binding to numerous SARS-CoV-2 variants that escape other antibodies .

Fine epitope mapping and structural studies have revealed that ADG2 employs a distinct angle of approach to recognize this conserved epitope, which appears to be critical for its remarkable breadth and potency .

How do the binding kinetics of ADG2 compare to other clinical-stage antibodies?

While specific comparative binding kinetic data isn't fully detailed in the provided search results, we can extract that ADG2 binds with high affinity to receptor binding domains (RBDs) of 12/13 clade 1 SARS-like-CoVs, with a KD(APP) of 0.24–1.12 nM . This demonstrates strong binding across a range of viral targets.

The search results indicate that ADG2 displays similar or higher neutralization potency against SARS-CoV-2 compared to other monoclonal antibodies in clinical development . For SARS-CoV-2 specifically, ADG2 shows an IC50 of approximately 1 ng/mL, which is comparable to or better than clinical-stage antibodies . For SARS-CoV, ADG2 demonstrates IC50 values between 4-8 ng/mL, showing stronger cross-reactive potency than most competing antibodies .

What experimental models have been used to evaluate ADG2's efficacy?

ADG2's efficacy has been evaluated through several experimental models:

• In vitro neutralization assays:

  • MLV-SARS-CoV-2 pseudovirus assay

  • Authentic SARS-CoV-2-nLuc neutralization assay

  • Neutralization testing against authentic SARS-CoV and bat SARS-related viruses

• Binding assays:

  • Yeast surface display platform to assess binding to 30 frequently observed SARS-CoV-2 RBD variants and 6 naturally circulating variants reported to be resistant to certain antibodies

  • Binding evaluations against RBDs from different sarbecoviruses

• Animal models:

  • Mouse models of SARS and COVID-19 were used to demonstrate protective efficacy

  • ADG2 provided complete protection against severe SARS-CoV-2 and SARS-CoV disease in these models

• Fc-mediated effector function assays:

  • Complement deposition assays

  • Antibody-dependent cellular phagocytosis

  • Natural killer cell activation

These diverse experimental approaches provided comprehensive evaluation of both neutralizing and non-neutralizing protective mechanisms of ADG2.

How does ADG2 trigger Fc-mediated effector functions and why is this important?

ADG2 potently triggers multiple Fc-mediated effector functions in vitro, which may contribute to its protective efficacy beyond direct viral neutralization. Key findings include:

• ADG2 robustly recruits phagocytosis at levels comparable to benchmark antibodies S309 and REGN10987 .

• ADG2 demonstrates superior natural killer (NK) cell activation compared to both S309 and REGN10987 .

• ADG2 shows strong complement deposition capability, superior to S309 and comparable to REGN10987 .

These Fc-mediated effector functions are important because they represent additional mechanisms by which antibodies can clear viral infection beyond direct neutralization. They include:

• Antibody-dependent cellular cytotoxicity (ADCC)

• Antibody-dependent cellular phagocytosis (ADCP)

• Complement-dependent cytotoxicity (CDC)

The ability of ADG2 to trigger these functions robustly may contribute to its in vivo efficacy and could be particularly important for clearance of infected cells rather than just prevention of cell entry .

What are the implications of ADG2's properties for future pandemic preparedness?

ADG2's unique combination of potency and breadth has significant implications for pandemic preparedness:

• Pre-emptive stockpiling potential: As ADG2 neutralizes not only SARS-CoV-2 and its variants but also SARS-CoV and related bat coronaviruses, it represents a promising candidate for therapeutic stockpiling to prevent or mitigate future outbreaks of SARS-related coronaviruses .

• Blueprint for "pan-SARS" vaccines: The conserved epitope targeted by ADG2 represents an attractive target for rational design of "pan-SARS" vaccines that aim to elicit similarly broadly protective antibodies .

• Model for broad-spectrum antiviral development: The engineering approach used to develop ADG2 demonstrates that broadly neutralizing antibodies can be engineered for improved neutralization potency while retaining neutralization breadth .

The recurrent zoonotic spillover of coronaviruses into human populations, combined with the broad diversity of SARS-like coronaviruses circulating in animal reservoirs, suggests that new pathogenic coronaviruses are likely to emerge in the future . ADG2-like antibodies provide a potential countermeasure against such threats.

What challenges exist in developing broadly neutralizing antibodies like ADG2?

While ADG2 represents a significant achievement in broadly neutralizing antibody development, several challenges exist in this field:

• Balancing breadth and potency: Most antibodies trade off breadth for potency - they either show broad activity against multiple coronaviruses but lack neutralization potency, or they show high neutralization potency against SARS-CoV-2 but lack activity against other coronaviruses . ADG2 is notable for achieving both.

• Limited availability of broadly neutralizing antibodies: The research indicates that broadly neutralizing antibodies like ADG2 are rare , making their discovery challenging.

• Translating in vitro findings to clinical efficacy: While ADG2 and similar antibodies show promising results in laboratory and animal studies, translating these findings to human clinical efficacy requires extensive additional research.

• Maintaining efficacy against evolving variants: Although ADG2 binds all tested SARS-CoV-2 variants, the continued evolution of the virus may eventually produce variants that escape even broadly neutralizing antibodies.

• Engineering for optimal properties: The creation of ADG20 (the half-life extended version of ADG2) illustrates the need for additional engineering to optimize properties like half-life for clinical applications .